Clinical Trial Update: EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon [Phase 4]

View source ↗

Summary

Phase 4 study evaluating pharmacogenetics of phenprocoumon in preventing thrombotic events in venous thromboembolism and atrial fibrillation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Venous Thromboembolism

Drugs mentioned

• Phenprocoumon (phenprocoumon)

Snippet

Sponsor: Utrecht Institute for Pharmaceutical Sciences | Conditions: Venous Thromboembolism (VTE), Atrial Fibrillation (AF) | Phase 4 | Status: COMPLETED